This article is more than 5 years old. Information may no longer be current.

Clarion to distribute MGD product in Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TearScience, the manufacturer of LipiFlow for treatment of meibomian gland dysfunction, announced that Clarion Medical has been appointed Canadian distributor, providing TearScience's technologies to all Canadian provinces except Quebec.

Through this partnership, Clarion will enhance the accessibility of meibomian gland dysfunction (MGD) treatment to Canadian practices and patients, the company said in a press release.

“Clarion will improve our reach and ability to service the growing market for treatment of MGD,” Tom Chirillo, TearScience’s senior vice president of sales and marketing, said in the release.